Minister for Trade and Industry, Mr Gan Kim Yong, visits EDDC24 August 2022
Compounds against Tuberculosis developed by EDDC and NTU out-licensed to Neuro-Horizon Pharma2 August 2022
Made-In-Singapore Cancer Drug ETC-159 Advances In Clinical Trials3 June 2022
Boehringer Ingelheim Enters Global Licensing Agreement To Develop And Commercialize Innovative Antibodies From A*Star For Targeted Cancer Therapies2 June 2022
EDDC interviews AUM Biosciences CEO, Mr. Vishal Doshi14 March 2022
Everest Medicines to develop, commercialise EDDC's small molecules as potential COVID-19 oral antiviral treatments18 January 2022
10 November 2021 | The (Wnt)ing way: Fighting cancer with ETC-159 | EDDC NewsA review of ETC-159 thus far
18 August 2021 | EDDC and NTUC develop novel drug candidates to combat deadly, ancient disease | EDDC NewsEDDC and NTU develop potential drug candidates against tuberculosis
10 August 2021 | EDDC discovers small molecule inhibitors for COVID-19 and other coronavirus infections | A*STAR NewsEDDC discovers small molecules that are effective against SARS-CoV-2 and other coronavirus strains
19 July 2021 | Structural model of PORCN illuminates disease-associated variants and drug binding sites | BioRxivPre-print of paper on findings from PORCN structural model
05 May 2021 | EDDC and Hummingbird Bioscience enter into partnership to co-develop novel antibodies for cancer treatment| A*STAR newsPress Release announcing collaboration between Hummingbird Bioscience and EDDC to develop anti-cancer therapeutic antibody program
21 April 2021 | GenScript ProBio enters collaboration with Singapore Experimental Drug Development center (EDDC) to develop anti-fibrosis therapeutic antibody program | Cision: PR NewswirePress Release announcing collaboration between GenScript ProBio and EDDC to develop anti-fibrosis therapeutic antibody program.
5 February 2021 | MTI Second Minister, Dr. Tan See Leng, visits EDDC| EDDC newsSummary of MTI Second Minister’s visit to EDDC
12 January 2021 | Scientists uncover how the Wntless protein carries Wnts in its signalling pathways | PhysOrgCrucial insights into Wnt signaling pathways uncovered
04 January 2021 | Ligature Therapeutics launches, raises USD $6M in seed financing | GlobeNewswireEDDC’s first spin-off, Ligature Therapeutics, raises USD 6M in seed financing
21 December 2020 | Experimental drug development centre launches spin-off to develop targeted protein degraders for treating intractable diseases |Bio SpecturmEDDC launches first spin-off – Ligature Therapeutics
16 November 2020 | Covid-19 and their role in war against pandemic | The Straits TimesContributed by Dr. Damian O’ Connell and Dr. David Lye
14 November 2020 | A Japanese who supported the development of PCR test kits in Singapore. How was it possible to increase kit production in its early days?| The Asahi Shimbun (online)An interview with Dr. Masafumi Inoue26 October 2020 | The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody | bioRxviv Preprint Server for BiologyPre-print paper contributed by EDDC CEO and staff
30 September 2020 | Singapore’s EDDC to discover new AI-driven COVID-19 therapies| BioSpectrum (Asia Edition)Collaboration with AI pharmaceutical specialist, Auransa, to develop new COVID-19 therapies
29 August 2020 | Pandemic powering demand for Singapore's pharma exports| The Straits TimesUpdate on biopharma scene in Singapore and EDDC’s potential role
30 July 2020 | Made-in-Singapore cancer drug ETC-159 advances further in clinical trials| ACN Newswire – Asiaone.comNew developmental milestone achieved for EDDC drug product
27 July 2020 | The fast track to a ‘Fortitude Kit’ for rapid diagnosis| Medical XpressCo-development of Singapore’s first RT-PCR SARS-CoV-2 diagnostic kit by Dr. Masafumi Inoue
9 February 2020 | Coronavirus: Made-in-Singapore diagnostics test implemented in hospitals here| The Straits TimesImplementation of coronavirus diagnostic kit co-developed by EDDC in public hospitals
19 September 2019 | September 2019 BRACE award competition | AFCR webpageEDDC project on ETC-159 awarded winner at the first ever BRACE Award Venture Competition
The A*STAR Experimental Drug Development Centre’s (EDDC) project on ETC-159, a novel small molecule drug candidate for colorectal cancer and other solid tumours was selected as the winner of the inaugural Bridging Research from Academia to Cancer Entrepreneurship (BRACE) competition in September 2019. The project was presented by EDDC Chief Development Officer, Dr Joel Leong. This competition was launched by the Asian Fund for Cancer Research (AFCR), a non-profit organisation committed to curing cancers that have significant impact on Asian populations. Click here to find out more about the 2019 BRACE competition.
26 June 2019 | National platform launched to boost Singapore’s drug development efforts | A*STAR Publicity HighlightsOfficial opening ceremony of EDDC
On 26 June, Mr Heng Swee Keat, Deputy Prime Minister and Minister for Finance, and Chairman of the National Research Foundation (NRF) officially opened the Experimental Drug Development Centre (EDDC), a national platform for drug discovery and development to channel high potential drug candidates toward commercial and clinical outcomes. The new centre integrates A*STARs Experimental Therapeutics Centre (ETC), the Drug, Discovery and Development (D3) unit, and the Experimental Biotherapeutics Centre (EBC) and will build on the combined capabilities we have developed over the years to support our partners in efforts to discover and develop innovative medicines. Click here to read the full article.
19 December 2018 | AUM Biosciences licenses cancer drug from A*STAR| AsianScientistBiotech firm obtained global rights to selective anticancer drug developed by ETC
04 December 2018 | AUM Biosciences acquires novel anti-cancer drug| BioSpectrum (Asia Edition)Biotech firm obtained global rights to selective anticancer drug developed by ETC
Calling all business owners!Learn from industry experts and adopt ready solutions to achieve sustainable business growth in today's fast-changing landscape.
Register to visit A*STAR@SWITCH now!